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Objective: To explore the function and mechanism of microRNA-155 to regulate the
angiogenesis after the cerebral infarction of rats through the angiotensin II receptor 1
(AT1R)/vascular endothelial growth factor (VEGF) signaling pathway.
Methods: Female SD rats were chosen for the construction of cerebral infarction model
of rats using the modiﬁed right middle cerebral artery occlusion. The real-time PCR (RT-
PCR) method was employed to detect the expression of microRNA-155 in each group at
different time points after the cerebral infarction (1 h, l d, 3 d and 7 d). SD rats were
randomly divided into four groups (n = 20 rats): sham operation group (Sham group),
MACO group, MACO+microRNA-155 mimic group, and MACO+microRNA-155 in-
hibitor group. Sham group was given the free graft, while MACO+microRNA-155 mimic
group and MACO+microRNA-155 inhibitor group were treated with microRNA-155
mimic and microRNA-155 inhibitor respectively. The Zea Longa 5-point scale was
used to score the neurologic impairment of rats in each group; 2, 3, 5-triphenyl tetra-
zolium chloride staining to evaluate the volume of cerebral infarction of rats in each
group; the immunohistochemistry to detect the expression of CD31; Western blot and
RT-PCR to detect the expression of AT1R and VEGF receptor 2 (VEGFR2).
Results: The expression of microRNA-155 was increased in the cerebral ischemia tissue
after the cerebral infarction. It was signiﬁcantly increased at 1 d of ischemia and maintained
at the high level for a long time. Rats in the Sham group had no symptom of neurologic
impairment, while rats in the MACO group had the obvious neurologic impairment. After
being treated with microRNA-155 inhibitor, the neural function of MACO rats had been
improved, with the decreased area of cerebral infarction. But after being treated with
microRNA-155 mimic, the neural function was further worsened, with the increased area
of cerebral infarction. Results of immunohistochemical assay indicated that microRNA-
155 inhibitor could up-regulate the expression of CD31, while microRNA-155 mimic
could down-regulate the expression of CD31. The RT-PCR found that, after being treated
with microRNA-155 inhibitor, MACO rats had the increased expression of AT1R and
VEGFR2 messenger RNA (mRNA); but after being treated with microRNA-155 mimic,
the expression of AT1R and VEGFR2 mRNA was decreased. Results of Western blot
showed that, after being treated with microRNA-155 inhibitor, MACO rats had the
increased expression of AT1R and VEGFR2 mRNA; but after being treated with
microRNA-155 mimic, the expression of AT1R and VEGFR2 mRNA was decreased.
Conclusions: The inhibition of microRNA-155 can improve the neurologic impairment
of rats with the cerebral infarction, reduce the volume of cerebral infarction and effec-
tively promote the angiogenesis in the region of ischemia, which may be mediated
through AT1R/VEGFR2 pathway.ndong University, No. 324 Nanjingwu Road,
pen access article under the CC BY-NC-ND
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The epidemiological survey shows the upward trend of
incidence of cerebral infarction in China, which has attracted a
wide attention because of its high disability rate and mortality
rate. The cerebral infarction can cause the irreversible degener-
ation and necrosis of brain neurons and thus lead to a series of
neurological dysfunction. Therefore, the pursuit of effective
means to early promote the local angiogenesis in the region of
cerebral infarction to recover the tissue perfusion will be of
critical signiﬁcance for the prognosis of patients with cerebral
infarction. But there are still no effective therapeutic programs.
The angiogenesis could improve the perfusion in the region
of cerebral infarction and thus promote the regeneration of
central nerve, as the basis for the recovery of brain neurons [1,2].
The vascular endothelial growth factor (VEGF) is one of the
most important vascular growth factors in the process of
angiogenesis. It's reported that its speciﬁc effect on the
endothelial cells could be involved in the angiogenesis [3].
VEGF plays its role through three receptors, including VEGF
receptor 1 (VEGFR1), VEGF receptor 2 (VEGFR2) and
VEGF receptor 3 (VEGFR3), where VEGFR2 is of most
important for the early angiogenesis. Angiotensin II (Ang II)
is a multifunctional bioactive peptide, which can promote the
angiogenesis and plays the key role in the angiogenesis.
Angiotensin II receptor 1 (AT1R)/VEGFR2 signaling pathway
can promote the proliferation and migration of vascular
endothelial cells and play a role in regulating the angiogenesis
both in the physiological and pathological condition.
According to researches, the angiogenesis began at the time of
cerebral infarction, and the regulation of AT1R/VEGFR2
pathway on the angiogenesis has been widely recognized [4].
However, when the cerebral infarction occurred, such reaction
of the body still could not improve the revascularization in the
region of cerebral infarction and the perfusion of brain tissue.
Therefore, it would be necessary to seek the effective
measures to enhance the role of AT1R/VEGFR2 pathway in
such process.
microRNA is some kind of small non-coding RNA molecule
with about 22 nucleotides, which can be widely found in the
plants, animals and some viruses [5]. Based on the
complementary pairing with messenger RNA (mRNA) of the
target gene, the microRNA can play a critical role in the gene
regulation after the silencing and transcription of RNA. Some
researchers found that microRNA could be widely involved in
the biological processes of proliferation, apoptosis and
differentiation of cells and play a key role in the regulation of
onset and development of many diseases (cardiovascular
diseases and tumors) [6,7]. It's reported that there was the close
relationship between microRNA-155 and angiogenesis and the
target gene of microRNA-155 was AT1R, which could target at
reducing the expression of AT1R [8] to inhibit Ang II/AT1R
signaling pathway and thus result in the inhibition of
angiogenesis. A research found that the expression of
microRNA-155 was signiﬁcantly increased in the condition of
cerebral ischemia, while the inhibition of microRNA-155 could
protect the nerves and thus improve the damage of cerebral
ischemia [9].
Consequently, this study was to build the cerebral infarction
model of rats. According to the in vivo over-expression and the
inhibition against the expression of microRNA-155, it was to
observe the effect of microRNA-155 on the angiogenesis of ratswith cerebral infarction and further explore the role of AT1R/
VEGFR2 pathway in such process.
2. Materials and methods
2.1. Materials
Adult female SD rats with the weight of about 200–250 g
were chosen as the subjects in this study (which were purchased
from Shanghai SLAC Laboratory Animal Co. Ltd.); other ma-
terials included RNA extraction kit (Invitrogen, USA); reverse
transcription kit (Takara, Japan); Real-time ﬂuorescent quanti-
tative PCR kit (TaKaRa, Japan); microRNA-155 mimic (Life
Technologies, USA); microRNA-155 inhibitor (Life Technolo-
gies, USA); triphenyl tetrazolium chloride (TTC) (Sigma, USA);
Rat CD31, AT1R, VEGFR2, b-actin antibody (Santa Cruz,
USA); horseradish peroxidase-labeled goat anti-rabbit IgG
(Beijing Zhongshan Golden Bridge Biotechnology Co., Ltd.).
2.2. Methods
2.2.1. Construction of cerebral infarction model of rats
Adult female SD rats (200–250 g) were fed in the single
cage at the room temperature of about 25 C and humidity of
about 50%, with the light/dark cycle of 12 h. They were given
with diet and water freely. After one week of adaptive feeding,
rats were given the intraperitoneal injection of pentobarbital
sodium (0.3 mL/100 g) for the anesthesia. The right middle
cerebral artery occlusion was performed on rats under sterile
conditions. Referring to the modiﬁed Zea-Longa method [10],
the speciﬁc procedures were as follows: the incision was
taken in the middle of neck and the tissues were separated
layer by layer to expose and free the right common carotid
artery, internal carotid artery and external carotid artery. A
small incision was taken in the external carotid artery close
to the heart. The suture was inserted in the common carotid
artery through the incision and then taken back to pass by
the bifurcation of common carotid artery and enter in the
internal carotid artery. Afterwards, the suture was slowly
delivered to the starting point of middle cerebral artery, with
the insert length of about (8.0 ± 0.5) cm from the bifurcation
of common carotid artery. The suture was ﬁxed and the neck
skin was stitched. Rats in the sham operation group (sham
group) were only freed the vessels. According to Zea-Longa
5-point scale (Table 1), the neurologic impairment of rats in
each group was scored [11].
2.2.2. Grouping
Laboratory rats were randomly divided into four groups
(n = 20 rats): Sham group, MACO group, MACO+microRNA-
155 inhibitor group and MACO+microRNA-155 mimic group.
At 5 min of sham operation for rats in the sham group, they were
injected with the equal normal saline through the lateral
ventricle; at 5 min of cerebral ischemia, rats in the MACO group
were injected with the equal normal saline through the lateral
ventricle; at 5 min of cerebral ischemia, rats in the
MACO+microRNA-155 mimic group were injected with 10 mg
miRNA-155 mimic through the lateral ventricle; at 5 min of
cerebral ischemia, rats in the MACO+microRNA-155 inhibitor
group were injected with 10 mg microRNA-155 inhibitor
through the lateral ventricle.
Table 1
Score of neurologic impairment of rats with cerebral infarction.
Score Degree of neurologic
impairment
Symptom
0 point Normal No symptom of neurologic
impairment
1 point Mild focal neurologic
impairment
Side front paw could not
stretch completely




3 points Severe focal neurologic
impairment
Tilted inwards when walking
4 points Critical neurologic
impairment
Failed to spontaneously walk
and loss of consciousness
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Referring to the instruction manual of trizol kit (Invitrogen),
the total RNA was extracted in the condition without RNAase.
The primer design was as follows, miR-155 upstream primer: 50-
GTCGTATCCAGTGCAGGGTCCGAGG-30, downstream
primer: TATTCGCACTGGATACGACCCCCTA. RNA was
reverse-transcripted into cDNA through one-step real-time PCR
(RT-PCR) kit. After PCR ampliﬁcation, 5 mL ampliﬁcation
products were collected and further tested using 2% agarose gel.
The UV spectrophotometer was used to detect the electropho-
retic band and photograph it.
2.2.4. Evaluation of volume of cerebral infarction by
TTC staining
Rats in each group were given the intraperitoneal injection of
0.3 mL/100 g pentobarbital sodium for the anesthesia. The chest
was cut off to expose the heart and the heart was perfused with
the normal saline. The brain tissue was then completely taken
out and cut into slices with the thickness of about 2 mm along
the coronal plane. They were sunk into 2% TTC normal saline
and incubated in a dark place and at 37 C. After 30 min, they
were photographed. The normal brain tissue appeared to be red,
while the region of cerebral infarction looked pale white. Image
Pro was employed to calculate the volume of cerebral infarction.
2.2.5. Detection of expression of CD31 by
immunohistochemical assay
After the intervention, the brain tissues were taken from the
ischemia area from rats in each group and they were ﬁxed with
4% paraformaldehyde. After being fully washed, they were
given the ethanol for the gradient dehydration. They were
transparent with xylene and imbedded and cut with the parafﬁn.
After the dewaxing and hydration of slices, the sodium citrate
was used to repair the antigen under the high pressure and 3%
H2O2 to block the endogenous peroxidase. The serum was
closed and the primary antibody (CD31) was added and incu-
bated overnight at 4 C. After being washed, the biotin-labeled
IgG was added for 10 min of incubation. When they were
washed, the streptin avidin–peroxidase was added for 10 min ofTable 2




b-actin TCCACCACCACAGCTGAGAGGincubation at the room temperature. They were colored with
DAB for 3 min and re-stained with hematoxylin for 10 s. Af-
terwards, they were differentiated with 1% hydrochloric acid–
alcohol for 2 s. They were mounted with the neutral resin and
then observed under the microscope.
2.2.6. Detection of expression of AT1R and VEGFR2
mRNA by RT-PCR
The total RNA was extracted from the brain tissue. The UV
spectrophotometer was employed to detect the concentration and
purity ofRNA.According to the instruction of reverse transcription
kit, cDNA was synthesized and stored at −80 C for further oper-
ation. SYBR method was employed for Real-time ﬂuorescent
quantitative PCR, with the reaction system of: SYBR PremixEx
Taq™ II (2×) 12.5 mL, 1.0 mL upstream and downstream primer
respectively, 2.0mLcDNAtemplate and8.0mLsterilizedwater; the
reaction conditions included: Initial denaturation (1 cycle) at 95 C
for 30 s; PCR reaction (40 cycles) at 95 C for 5 s and at 60 C for
30 s (collection of ﬂuorescence signal); melting (1 cycle) at 95 C
for 15 s; at 60 C for 30 s; and at 95 C for 15 s (collection of
ﬂuorescence signal). After the ampliﬁcation, it was followed by the
results analysis. Takingb-actin as the reference and according toCt
value of RT-PCR results, the relative expression of mRNA was
calculated. Each group had three parallel wells and the experiment
had three repeats (Table 2).
2.2.7. Detection of expression of CD31, AT1R and
VEGFR2 by Western blot
The protein was extracted from the brain tissue. The protein
assay was employed to detect the concentration of protein. Pro-
tein samples were given SDS-PAGE electrophoresis. They were
transferred to polyvinylidene ﬂuoride membrane using the semi-
dry transfer buffer. After being closed with 5% skimmed milk
powder for 1 h, the primary antibody that was diluted with TBST
(CD31, AT1R, VEGFR2, b-actin) was added and then incubated
at 4 C overnight. The membrane was washed with TBST for
three times and then the horseradish peroxidase-labeled second-
ary antibody was added and incubated at the room temperature
for 1 h. Afterwards, it was washed with TBST for three times.
The gel imaging analysis system was used to scan the density of
bands and determine the gray-level integration.
2.3. Statistical analysis
All data was treated with SPSS 19.0. The measurement data
was expressed by mean ± SD. Levene test was used for the
homogeneity of variance test (reference standard of 0.10).
Means of each group that met the homogeneity of variance were
treated with one-way ANOVA and LDS test, means that not met
the homogeneity of variance were treated with Kruskal–Wallis
H test. The pairing t test was used for the comparison before and





Figure 2. Effect on expression of microRNA-155.
Compared with the MACO group, **P < 0.01.
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3.1. Change in expression of microRNA-155 of cerebral
ischemia tissue after the cerebral infarction
The expression of microRNA-155 of cerebral ischemia tissue
after the cerebral infarction was detected at 1 h, 1 d, 3 d and 7 d
of cerebral infarction. Results showed that the expression of
microRNA-155 at each time point after the ischemia was
signiﬁcantly higher than the one in the sham group (P < 0.05).
The expression of microRNA-155 was increased even at 1 h of
ischemia, while it was signiﬁcantly increased at 1 d of ischemia
(P < 0.01) and maintained at the high level for a long time (till
7 d) (Figure 1).
3.2. In vivo effect on expression of microRNA-155
The microRNA mimic can simulate the endogenous micro-
RNA and thus up-regulate the expression of microRNA and
enhance its function. But microRNA inhibitor can speciﬁcally
target at knocking down the microRNA and thus down-regulate
the expression of microRNA. In this study, MACO rats were
given the microRNA-155 mimic and microRNA-155 inhibitor
and then RT-PCR was employed to detect the expression of
microRNA-155 in the brain tissue of rats in each group. Results
showed that, compared with the MACO group, the expression of
microRNA-155 in the microRNA-155 mimic group was
signiﬁcantly increased (P < 0.01), while it was signiﬁcantly
decreased in the microRNA-155 inhibitor group (P < 0.01)
(Figure 2).
3.3. Effect of microRNA-155 on neural function and
area of cerebral infarction of MACO rats
As shown in Table 3, rats in the sham group had no
symptom of neurologic impairment, while the score of neuro-
logic impairment for rats in the MACO group was 2.77 ± 0.64.
After being treated with the microRNA-155 inhibitor, the scoreFigure 1. Change in expression of microRNA-155 of cerebral ischemia
tissue.
Compared with the sham group, **P < 0.01.of neurologic impairment was decreased than the one in the
MACO group (P < 0.05), but after being treated with the
microRNA-155 mimic, the score of neurologic impairment was
increased (P < 0.05). Results of TTC staining showed that,
after being treated with the microRNA-155 inhibitor, its area of
cerebral infarction was decreased (P < 0.05), while after being
treated with the microRNA-155 mimic, its area of cerebral
infarction was increased. Above results indicated that the in-
hibition of microRNA-155 could improve the neurologic
function and reduce the volume of cerebral infarction of
MACO (Table 3).
3.4. Effect of microRNA-155 on expression of CD31 in
cerebral ischemia tissue after cerebral infarction
CD31 is mainly distributed in vascular endothelial cells and
it is usually used to evaluate the vessel density in the tissue.
Thus in this study, the immunohistochemistry was employed
to further detect the expression of CD31 in the cerebral
ischemia tissue after cerebral infarction, as shown in
Figure 3A. Results indicated that, compared with the sham
group, there was no signiﬁcant change in the expression of
CD31 in the brain tissue after ischemia (P > 0.05), as shown in
Figure 3B. After being treated with microRNA-155 inhibitor,
the expression of CD31 was signiﬁcantly increased (P < 0.05),
as shown in Figure 3C; while after being treated with
microRNA-155 mimic, the expression of CD31 was signiﬁ-
cantly decreased (P < 0.05), which indicated that the inhibition
of microRNA-155 could promote the angiogenesis after cere-
bral infarction (Figure 3B).Table 3
Score of neurologic impairment and volume of cerebral infarction of rats
in each group (mean ± SD, n = 8).




Sham group 0.00 0.00
MACO group 2.77 ± 0.64* 29.26 ± 2.17*
MACO+microRNA-155
inhibitor group
2.01 ± 0.78# 24.12 ± 1.64#
MACO+microRNA-155
mimic group
3.45 ± 0.81# 37.22 ± 2.98#
Compared with the sham group, *P < 0.05; Compared with the MACO
group, #P < 0.05.
Figure 4. Effect of microRNA-155 on expression of CD31 in the cerebral
ischemia tissue after cerebral infarction by Western blot.
Compared with the MACO group, **P < 0.01.
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cerebral ischemia tissue after cerebral infarction
As shown in Figure 4, results of Western blot indicated that,
compared with the sham group, there was no signiﬁcant change
in the expression of CD31 in the brain tissue after ischemia
(P > 0.05). After being treated with microRNA-155 inhibitor,
the expression of CD31 was signiﬁcantly increased (P < 0.05);
while after being treated with microRNA-155 mimic, the
expression of CD31 was signiﬁcantly decreased (P < 0.05),
which indicated that the inhibition of microRNA-155 could
promote the angiogenesis after cerebral infarction.
3.6. Effect of microRNA-155 on expression of AT1R and
VEGFR2 protein in cerebral ischemia tissue after
cerebral infarction
In this study, Western blot was employed to further detect the
expression of AT1R and VEGFR2 protein in the cerebral
ischemia tissue after cerebral infarction, which was consistent
with the change in the expression of mRNA. To be speciﬁc, after
being treated with microRNA-155 inhibitor, the expression of
AT1R and VEGFR2 protein was signiﬁcantly increased
(P < 0.05), while being treated with microRNA-155 mimic, the
expression of AT1R and VEGFR2 protein was signiﬁcantly
decreased (P < 0.05, Figure 5), which indicated that the inhi-
bition of microRNA-155 could promote the angiogenesis afterFigure 3. Effect of microRNA-155 on expression of CD31 in the cerebral ischemia tissue after cerebral infarction by immunohistochemical assay.
Compared with the MACO group, **P < 0.01.
Figure 5. Effect of microRNA-155 on expression of AT1R and VEGFR2 protein.
Compared with the MACO group, **P < 0.01.
Figure 6. Effect of microRNA-155 on expression of AT1R and VEGFR2
mRNA.
Compared with the MACO group, **P < 0.05.
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VEGFR2 pathway.
3.7. Effect of microRNA-155 on expression of AT1R and
VEGFR2 mRNA in cerebral ischemia tissue after
cerebral infarction
The detection on the expression of AT1R and VEGFR2
mRNA in the cerebral ischemia tissue after cerebral infarction
showed that, compared with the sham group, there was no sig-
niﬁcant change in the expression of AT1R and VEGFR2 mRNA
in the brain tissue after ischemia (P > 0.05). After being treated
with microRNA-155 inhibitor, the expression of AT1R and
VEGFR2 mRNA was signiﬁcantly increased (P < 0.01); while
after being treated with microRNA-155 mimic, the expression of
AT1R and VEGFR2 mRNA was signiﬁcantly decreased
(P < 0.01, Figure 6).
4. Discussion
The cerebrovascular diseases have become one of important
cause for human death, where most of them are the ischemic
cerebrovascular diseases, accounting for about 75%–85% of thetotal. The cerebral infarction can cause the irreversible degen-
eration and necrosis of brain neurons and thus lead to a series of
neurological dysfunction, bringing along the huge burden to
patients, their families and society [12]. For patients with cerebral
infarction, the main treatments included the symptomatic
treatment, neuroprotection and anti-thrombin thrombolysis [13].
With the in-depth studies in this ﬁeld, researchers proposed
the concept of penumbra zone of cerebral ischemia in recent
years, namely the relative ischemic zone around the central zone
of ischemia of cerebral infarction. Because of the support of
collateral circulation in such zone, lots of neurons only had the
reversible degeneration and the early recovery of blood supply
could reverse the degeneration and necrosis. According to
clinical researches, the higher density of neovascularization in
the zone of cerebral ischemia of stroke patients would lead to the
better clinical prognosis [14]. Therefore, the pursuit of effective
means to early promote the local angiogenesis in the region of
cerebral infarction to recover the tissue perfusion will be of
critical signiﬁcance for the prognosis of patients with cerebral
infarction. But there are still no effective therapeutic programs.
microRNA is some kind of small non-coding RNA molecule,
which can degrade the target gene mRNA and play a critical role
in the gene regulation [15]. Some researchers found that
microRNA could be widely involved in the biological
processes of proliferation, apoptosis and differentiation of cells
and play a key role in the regulation of onset and
development of many diseases (cardiovascular diseases and
tumors). According to the regulation of related target genes,
microRNA could be involved in many pathological and
physiological processes after the cerebral ischemia, which
could inhibit some microRNA and protect the nerve of
patients with the brain injury [16,17]. It's reported that, in the
situation of many brain injuries, the expression of microRNA-
155 was increased in the brain tissue, which indicated that
microRNA-155 might be related to the brain injury [18]. In this
study, the expression of microRNA-155 in the cerebral
ischemia tissue was increased even at 1 h of cerebral infarction,
while it was signiﬁcantly increased at 1 d of ischemia and
maintained at the high level for a long time, which indicated that
the over-expression of microRNA-155 after cerebral ischemia
was involved in the injury of brain tissue. To specify the func-
tion of microRNA-155 in the injury of brain tissue after cerebral
infarction, the microRNA mimic was used to up-regulate the
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regulate the expression of microRNA. Results showed that
microRNA-155 inhibitor could improve the neurological func-
tion of MACO rats and reduce the volume of cerebral infarction;
while microRNA-155 mimic would further worsen the neuro-
logical function of MACO rats and increase the volume of ce-
rebral infarction.
According to previous researches, it's reported that there was
the close relationship between microRNA-155 and angiogenesis
and the brain angiogenesis was the foundation for the tissue
repair in the ischemic zone. The new blood vessels can not only
improve the micro circulation in the zone of cerebral ischemia
and inhibit the apoptosis of nerve cells, but also induce the
release of nutritional factors to promote the recovery of neuro-
logical function. It can thus be presumed that the reason for the
inhibition of microRNA-155 to improve the neurological func-
tion of rats with cerebral infarction may be the action to promote
the angiogenesis. CD31 is the endothelial cell adhesion mole-
cule, which can be expressed in the vascular endothelium and
has become the common indicator of angiogenesis in the clinical
practice. According the further detection of expression of CD31
in the cerebral ischemia tissue after, it's found that microRNA-
155 mimic could inhibit the expression of CD31. After being
treated with microRNA-155 inhibitor, the expression of CD31
was signiﬁcantly increased, indicated that the inhibition of
microRNA-155 could promote the angiogenesis after cerebral
infarction. Ang II is a multifunctional bioactive peptide, which
can promote the angiogenesis and plays the key role in the
angiogenesis [19]. It's found that the target gene of microRNA-
155 is the receptor of Ang II, AT1R. The microRNA-155 can
target at decreasing the expression of AT1R, inhibit the Ang II/
AT1R signaling pathway and thus inhibit the angiogenesis. In
this study, results showed that microRNA-155 mimic could
inhibit the expression of AT1R in the cerebral ischemia tissue,
while microRNA-155 inhibitor could promote the expression of
AT1R in the cerebral ischemia tissue. In the process of angio-
genesis, it requires the synergistic action of many factors, where
the most important one is VEGF. VEGF is some kind of speciﬁc
mitogen of vascular endothelial cells, which can not only stim-
ulate the proliferation and migration of endothelial cells and
promote the fusion of capillary, but also mobilize the endothelial
cells to enter in the avascular zone and promote the angiogen-
esis. VEGF plays its role through three receptors of VEGFR1,
VEGFR2 and VEGFR3, where VEGFR2 is of most critical for
the early angiogenesis. The knockdown of VEGFR2 in the
embryonic stage might result in the deletion of vascular cells
[20]. Ang II could promote the expression of VEGFR2 through
the dose-dependent AT1R and enhance the VEGFR2-mediated
proliferation and angiogenesis of cells [21]. In this study, it's
found that microRNA-155 mimic could inhibit the expression
of VEGFR2 in the cerebral ischemia tissue after cerebral
infarction, while microRNA-155 inhibitor could promote the
expression of VEGFR2 in the cerebral ischemia tissue after
cerebral infarction, which indicated that microRNA-155 might
regulate the angiogenesis through AT1R/VEGFR2 pathway.
In conclusion, according to the over-expression and inhibited
expression of microRNA-155 in the cerebral infarction model of
rats, it shows that the inhibition of microRNA-155 can improve
the neurologic impairment of rats with the cerebral infarction,
reduce the volume of cerebral infarction and effectively promote
the angiogenesis in the region of ischemia, which may be
mediated through AT1R/VEGFR2 pathway.Conﬂict of interest statement
We declare that we have no conﬂict of interest.
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